A groundbreaking scientific inquiry is reshaping the established understanding of Alzheimer’s disease (AD), suggesting that the relentless progression of this neurodegenerative condition may not be an irreversible fate. For over a century, the prevailing scientific consensus has characterized AD as a degenerative process from which the brain cannot recover, leading research endeavors to primarily concentrate on preventative measures or strategies to decelerate its advancement. Despite substantial investments in research and development over many decades, the landscape of Alzheimer’s therapeutic interventions has largely been confined to slowing decline, with no drug trials historically designed with the explicit objective of restoring cognitive faculties lost to the disease. This long-standing paradigm, however, is now being critically re-examined by a collaborative team of scientists affiliated with University Hospitals, Case Western Reserve University, and the Louis Stokes Cleveland VA Medical Center. Their ambitious research initiative was conceived to address a profound and challenging question: can the brain, once significantly impacted by advanced Alzheimer’s pathology, regain its lost functionality?
At the core of this novel research lies an investigation into a fundamental biological impairment: the failure of brain cells to adequately manage their energy resources. The study, spearheaded by Dr. Kalyani Chaubey of the Pieper Laboratory and published in the journal Cell Reports Medicine, meticulously examined both human brain tissue afflicted with Alzheimer’s and a variety of preclinical mouse models engineered to mimic the disease. Through this comprehensive analysis, the researchers identified a critical deficit in the brain’s ability to sustain optimal levels of nicotinamide adenine dinucleotide (NAD+), a vital cellular energy currency. Their findings underscore that the disruption of NAD+ homeostasis plays a pivotal role in driving the pathological cascade of Alzheimer’s. Crucially, the research demonstrated that maintaining a balanced NAD+ supply not only served to prevent the onset of Alzheimer’s-like pathology but, more remarkably, could also reverse existing damage in experimental settings.
The natural aging process is accompanied by a gradual decline in NAD+ levels throughout the body, including within the brain. When NAD+ concentrations fall below a certain threshold, cells are compromised in their capacity to execute essential functions critical for their survival and optimal operation. The investigative team observed that this age-related depletion of NAD+ is significantly more pronounced in the brains of individuals diagnosed with Alzheimer’s disease. This same stark pattern was replicated in the genetically modified mouse models utilized in the study, providing a consistent biological signature of the disease.
To rigorously test their hypotheses, the scientists employed sophisticated mouse models that recapitulate key aspects of human Alzheimer’s disease. While Alzheimer’s is exclusively a human ailment, these specially developed rodents carry specific genetic mutations known to induce the disease in people. In this particular study, two distinct mouse lines were utilized. One group was engineered to harbor multiple human genetic alterations affecting the processing of amyloid precursor protein, a hallmark of AD. The second group carried a human genetic mutation affecting the tau protein, another protein central to AD pathology.
The aberrant accumulation and aggregation of amyloid-beta plaques and tau tangles are recognized as some of the earliest and most significant pathological hallmarks of Alzheimer’s disease. In both of the mouse models studied, these introduced mutations led to widespread neuronal damage that closely mirrored the pathological landscape observed in human Alzheimer’s brains. This damage encompassed the disintegration of the blood-brain barrier, structural damage to neuronal axons and dendrites, chronic neuroinflammation, a diminished capacity for neurogenesis (the formation of new neurons) in the hippocampus – a region critical for memory formation – impaired communication between neurons, and extensive oxidative stress. Concurrently, these mice exhibited severe impairments in memory and overall cognitive function, mirroring the clinical presentation of Alzheimer’s in human patients.
Following the confirmation that NAD+ levels were drastically reduced in both human and mouse Alzheimer’s brains, the research team embarked on exploring two critical therapeutic avenues. They investigated whether preserving NAD+ balance before the manifestation of Alzheimer’s symptoms could confer protection against disease development. Equally important, they sought to determine if restoring NAD+ balance after the disease had already progressed to an advanced stage could lead to a reversal of the damage. This investigative approach built upon the researchers’ prior work, published in the Proceedings of the National Academy of Sciences USA, which had previously demonstrated that re-establishing NAD+ homeostasis resulted in both structural and functional recovery following severe, long-standing traumatic brain injury. For the current study, the researchers employed a well-characterized pharmacological agent, P7C3-A20, developed within the Pieper laboratory, to effectively restore NAD+ balance in the experimental models.
The experimental outcomes were profoundly encouraging. The administration of NAD+ balance-preserving interventions successfully protected the mice from developing Alzheimer’s-like pathology. However, the most striking revelation emerged when treatment was initiated in mice with already advanced disease. In these instances, the restoration of NAD+ balance enabled the brain to undertake a remarkable repair process, mending the significant pathological damage induced by the underlying genetic mutations.
Across both distinct mouse models, a complete restoration of cognitive function was observed. This functional recovery was corroborated by biochemical analyses; blood tests revealed normalized levels of phosphorylated tau 217 (p-tau217), a recently approved clinical biomarker that is highly effective in diagnosing Alzheimer’s disease in humans. These findings provided robust evidence of disease reversal and highlighted a promising potential biomarker for future human clinical trials.
"We were profoundly excited and encouraged by the results of our study," stated Dr. Andrew A. Pieper, the senior author of the research and Director of the Brain Health Medicines Center at the Harrington Discovery Institute within University Hospitals. "By restoring the brain’s intrinsic energy regulation, we achieved both pathological and functional recovery in two distinct lines of mice afflicted with advanced Alzheimer’s disease. Observing this effect in two markedly different animal models, each driven by distinct genetic etiologies, significantly strengthens the hypothesis that the therapeutic restoration of brain NAD+ balance could offer a pathway to recovery for human patients suffering from Alzheimer’s." Dr. Pieper also holds esteemed professorial positions at University Hospitals and Case Western Reserve University and serves as a Psychiatrist and Investigator at the Louis Stokes VA Geriatric Research Education and Clinical Center (GRECC).
The implications of these findings suggest a paradigm shift in how Alzheimer’s disease might be approached therapeutically in the future. "The central takeaway from our research is a message of hope – the detrimental effects of Alzheimer’s disease may not be permanently ingrained," Dr. Pieper emphasized. "The damaged brain possesses an inherent capacity, under specific conditions, to initiate repair mechanisms and regain its functional capabilities." Dr. Chaubey further elaborated, "Through our investigation, we have demonstrated a drug-based method to achieve this reversal in animal models and have also identified candidate proteins within the human Alzheimer’s brain that may be indicative of the brain’s ability to reverse the disease process."
It is crucial to distinguish this experimental strategy from the use of over-the-counter NAD+-precursor supplements. Dr. Pieper cautioned against conflating the two, noting that studies in animal models have indicated that such supplements can elevate NAD+ levels to potentially hazardous extremes that may promote cancer. The methodology employed in this research relies instead on P7C3-A20, a carefully developed pharmacological agent that facilitates cells in maintaining healthy NAD+ homeostasis during periods of severe physiological stress, without driving NAD+ levels beyond their natural physiological range. "This distinction is of paramount importance when considering patient care, and clinicians should give serious consideration to the possibility that therapeutic strategies focused on restoring brain energy balance could offer a viable route toward disease recovery," Dr. Pieper advised.
This significant research also paves the way for further investigations and, ultimately, the initiation of human clinical trials. The underlying technology is currently in the process of being commercialized by Glengary Brain Health, a Cleveland-based company co-founded by Dr. Pieper. "This novel therapeutic approach aimed at recovery must now be rigorously evaluated in carefully designed human clinical trials to ascertain whether the efficacy observed in animal models translates to human patients," Dr. Pieper explained. "Additional future research priorities for the laboratory include precisely identifying which facets of brain energy balance are most critical for functional recovery, discovering and assessing complementary therapeutic strategies for Alzheimer’s reversal, and investigating whether this restorative approach also proves effective in other forms of chronic, age-related neurodegenerative disorders."
About the Author
